VAD chemotherapy as remission induction for multiple myeloma

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Multiple myeloma is a hematologic malignancy requiring effective remission induction therapies.
• The VAD regimen (Vincristine, Doxorubicin, Dexamethasone) is a standard treatment approach.
• Optimizing outpatient therapy is crucial for patient management and accessibility.

Purpose of the Study:

• To evaluate the efficacy and tolerability of VAD therapy for multiple myeloma remission induction.
• To compare outcomes in previously untreated versus relapsed/refractory multiple myeloma patients.
• To assess the role of VAD in patients undergoing subsequent stem cell transplantation.

Main Methods:

• A total of 142 multiple myeloma patients received VAD therapy.
• VAD consisted of continuous infusion vincristine and doxorubicin with oral dexamethasone over 4 days, repeated every 21 days.
• Patients were stratified into previously untreated and relapsed/refractory groups.

Main Results:

• Overall response rates were 84% in untreated and 61% in relapsed/refractory patients.
• Median survival was 36 months for untreated and 10 months for treated patients.
• VAD was generally well-tolerated, with common side effects including infections and dyspepsia.

Conclusions:

• VAD is an effective outpatient induction therapy for multiple myeloma.
• Outcomes differ significantly between previously untreated and relapsed/refractory patient populations.
• Further research is needed to optimize post-remission and consolidation strategies, particularly for relapsed/refractory disease.